Japan will fast-track a review of Gilead Sciences Inc's antiviral drug remdesivir so that it can hopefully be approved for domestic COVID-19 patients a week after the U.S. firm's filing for such approval, the health minister said on Saturday.
FILE PHOTO: Gilead Sciences Inc in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo
Health Minister Katsunobu Kato’s comment comes after remdesivir was granted emergency use authorization by the U.S. Food and Drug Administration for COVID-19 on Friday.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Gilead CEO on remdesivir: manufacturing, pricing for coronavirus drug - Business InsiderGilead plans to spend up to $1 billion to ramp up manufacturing of its coronavirus treatment, but execs dodged Wall Street's questions about turning a profit
続きを読む »
Gilead to work with partners to ramp up production of potential coronavirus treatmentGilead Sciences Inc , maker of the closely-watched experimental coronavirus drug remdesivir, on Thursday said it will work with international partners to expand production of the potential COVID-19 treatment.
続きを読む »
Maker of coronavirus trial drug aims for wide distribution: Gilead CEOGilead Sciences , which manufactures remdesivir, is focused on making the experimental coronavirus drug accessible and affordable to as many people as possible once it is approved, Chief Executive Officer Daniel O'Day said on Friday.
続きを読む »
FDA Authorizes Emergency Use of Gilead Drug Remdesivir for Covid-19 PatientsThe Food and Drug Administration’s move came after researchers reported that the Gilead drug shortened the recovery times in people who have fallen ill from the new coronavirus.
続きを読む »
Gilead gets emergency FDA authorization for remdesivir to treat coronavirus, Trump saysThe Food and Drug Administration has granted emergency use authorization for Gilead’s remdesivir drug to treat the coronavirus, President Donald Trump announced Friday.
続きを読む »
Gilead says it can produce 'several million' rounds of remdesivir coronavirus treatments next year“We’re just humbled and pleased by the results this week as a starting point for therapies in COVID-19.” Gilead CEO Daniel O’Day discussed the positive results released this week from 2 remdesivir studies.
続きを読む »